The
purpose of this study is to determine if subjects who switch
from olanzpine, quetiapine or risperidone to aripiprazole
show changes in body composition, weight, lipids, glucose,
(and other metabolic markers), energy expenditure or caloric
consumption after 14 weeks.
Inclusion
Criteria :
•
Between 18-65 years of age, any race and either gender.
•
Meets DSM IV criteria for a psychotic disorder (schizophrenia,
schizophreniform, brief psychotic disorder, schizoaffective
disorder).
•
Antipsychotic monotherapy with olanzapine, risperidone or
quetiapine for minimum of 1 month at entry into study and
with weight gain of 1 BMI units while on this medication
or development of abnormalities of glucose (greater than
110 mg/dl fasting), lipids (TC, HDL, TG, or LDL greater
than 10% change) or blood pressure (greater than 20 mmHg
change in systolic and diastolic)
•
Antipsychotic monotherapy with aripiprazole is planned by
the subject's treating psychiatrist.
•
Subjects able to fully participate in the informed consent
process
•
Female subjects of childbearing potential must be using
a medically accepted means of contraception which includes
tubal ligation, hysterectomy, condoms, oral contraceptives,
IUD, cervical cap, diaphragm, transdermal contraceptive
patch, and abstinence.
Exclusion
Criteria:
•
Subjects have had a previous trial of aripiprazole
•
Subjects receiving other medications known to affect weight
balance including depakote, lithium, tegretol, lamotragine,
mirtazapine, corticosteroids and stimulants (i.e. methamphetamine)
All concomitant medications will be reviewed by the study
physician.
•
Subjects are receiving over-the-counter weight loss medications
or are actively involved with a weight loss program.
•
Serious, unstable medical illness.
•
At serious suicidal risk.
•
Subjects with substance abuse or dependence.
•
Subjects with an eating disorder.
•
Female subjects who are either pregnant or nursing.
•
Known history of mental retardation or dementia
